MicroMatrices, Advanced Cell Diagnostics sign preferred partnership agreement

MicroMatrices becomes preferred partner for preclinical use of ACD’s RNA ISH

MicroMatrices, a service provider specialised in high resolution cell type-specific analysis to characterise toxicological responses in different cell types in tissue, today announced a preferred partnership agreement with Advanced Cell Diagnostics, Inc. (ACD), a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools.

MicroMatrices solves molecular toxicological problems using unique visualisation and localisation technologies, adding resolving power to standard methodologies. Consisting of a highly skilled core of scientists networked to facilities of excellence across the United Kingdom, MicroMatrices is scalable, efficient and flexible. MicroMatrices offers innovative, collaborative, state of the art solutions for unique efficacy and safety requirements.

MicroMatrices has been well known for immunohistochemistry (IHC) staining and has recently become expert in the use of ACD’s RNAscope® Technology to detect RNA based biomarkers in situ. This has resulted in unique expertise in combined protein/RNA co-detection and co-localisation to offer clients an exceptional target visualisation capacity which can guide and/or corroborate mechanistic and mode of action studies. In recognition of MicroMatrices’ extensive experience in applying RNAscope in preclinical toxicology investigations for safety and efficacy, ACD has begun a preferred partnership programme for the provision and/or development of preclinical applications of RNAscope Technology.

Dr Simon Plummer, Managing Director of MicroMatrices commented:

The power and versatility of RNAscope has been an invaluable tool to enable us to solve mode of action/efficacy/toxicity challenges for our clients in the pharmaceutical, agrochemical, and chemical industries. We are delighted to be partnering with ACD to promote the wider application of RNAscope technology in preclinical safety/drug development problem solving for our collaborators.

ACD's RNAscope assays represent a major technological advance for in situ RNA detection. For the first time, robust single RNA molecule detection is available for formalin-fixed, paraffin-embedded (FFPE) tissue offering quantitative molecular detection with morphological context in a single assay. Since their commercialisation three years ago, these assays have been adopted across the globe by major pharma biotech companies and leading research institutions for drug discovery, translational research, and the development of clinical and companion diagnostic tests.

“ACD has established high quality performance standards through RNAscope products and services and MicroMatrices is known for quality, service and expertise in the drug development community," said Dr Steve Chen, Chief Operating Officer of ACD. "As ACD's install base is growing very rapidly in Europe, they are an ideal partner not only to extend our reach but also to solidify our commitment in service quality.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Advanced Cell Diagnostics. (2019, June 19). MicroMatrices, Advanced Cell Diagnostics sign preferred partnership agreement. News-Medical. Retrieved on April 15, 2024 from https://www.news-medical.net/news/20141111/MicroMatrices-Advanced-Cell-Diagnostics-sign-preferred-partnership-agreement.aspx.

  • MLA

    Advanced Cell Diagnostics. "MicroMatrices, Advanced Cell Diagnostics sign preferred partnership agreement". News-Medical. 15 April 2024. <https://www.news-medical.net/news/20141111/MicroMatrices-Advanced-Cell-Diagnostics-sign-preferred-partnership-agreement.aspx>.

  • Chicago

    Advanced Cell Diagnostics. "MicroMatrices, Advanced Cell Diagnostics sign preferred partnership agreement". News-Medical. https://www.news-medical.net/news/20141111/MicroMatrices-Advanced-Cell-Diagnostics-sign-preferred-partnership-agreement.aspx. (accessed April 15, 2024).

  • Harvard

    Advanced Cell Diagnostics. 2019. MicroMatrices, Advanced Cell Diagnostics sign preferred partnership agreement. News-Medical, viewed 15 April 2024, https://www.news-medical.net/news/20141111/MicroMatrices-Advanced-Cell-Diagnostics-sign-preferred-partnership-agreement.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New website and online store released by Advanced Cell Diagnostics